Antinociceptive profiles and mechanisms of orally administered vanillin in the mice.
In the present study, the antinociceptive profiles of vanillin were examined in ICR mice. Vanillin administered orally (from 1 to 10 mg/kg) showed an antinociceptive effect in a dose-dependent manner as measured in the acetic acid-induced writhing test. Duration of antinociceptive action of vanillin maintained at least for 30 min. But, the cumulative response time of nociceptive behaviors induced by a subcutaneous (s.c.) formalin injection, intrathecal (i.t.) substance P (0.7 microg) or glutamate (20 microg) injection was not affected by vanillin. Intraperitoneal (i.p.) pretreatment with yohimbine (alpha2-adrenergic receptor antagonist) or naloxone (opioid receptor antagonist) attenuated antinociceptive effect induced by vanillin in the writhing test. However, phentolamine (alpha1-adrenergic receptor antagonist) or methysergide (5-HT serotonergic receptor antagonist) did not affect antinociception induced by vanillin in the writhing test. Our results suggest that vanillin exerts a selective antinociceptive property in the acetic acid-induced visceral inflammatory pain model. Furthermore, this antinociceptive effect of vanillin may be mediated by alpha2-adrenergic and opioid receptors, but not alpha1-adrenergic and serotonergic receptors.
Park
Soo-Hyun
SH
Department of Pharmacology, Institute of Natural Medicine, College of Medicine, Hallym University, Chuncheon 200-702, Korea.
Sim
Yun-Beom
YB
Choi
Seung-Min
SM
Seo
Young-Jun
YJ
Kwon
Min-Soo
MS
Lee
Jin-Koo
JK
Suh
Hong-Won
HW
D000284:Administration, Oral; D000700:Analgesics / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D001547:Benzaldehydes / Q000008:administration & dosage / Q000494:pharmacology*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D007249:Inflammation / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D010146:Pain / Q000188:drug therapy* / Q000503:physiopathology; D018341:Receptors, Adrenergic, alpha-2 / Q000378:metabolism; D011957:Receptors, Opioid / Q000378:metabolism
D000700:Analgesics; D001547:Benzaldehydes; D018341:Receptors, Adrenergic, alpha-2; D011957:Receptors, Opioid; C100058:vanillin